Continue Febuxostat and Increase the Dose
Your patient is already on febuxostat with an uncontrolled uric acid of 9.8 mg/dL—you should continue febuxostat and titrate the dose upward rather than switching to allopurinol. The question of "giving febuxostat instead of allopurinol" is moot since the patient is already taking febuxostat; the real issue is that the current dose is inadequate.
Why Continue Febuxostat
The 2020 ACR guidelines establish allopurinol as the preferred first-line agent for gout 1. However, once a patient is already established on febuxostat, there is no compelling reason to switch to allopurinol—particularly when the problem is simply inadequate dosing, not drug failure or intolerance.
Dose Titration is Key
- Start-and-titrate approach: Both allopurinol and febuxostat should be started at low doses (febuxostat ≤40 mg/day) and titrated upward to achieve target uric acid <6.0 mg/dL 1
- Your patient's uric acid of 9.8 mg/dL indicates the current febuxostat dose is insufficient—this is a dosing problem, not a drug selection problem
- Febuxostat can be increased from 40 mg to 80 mg daily, and studies show 80 mg febuxostat achieves target uric acid in 48-69% of patients compared to only 22% with standard-dose allopurinol 2
Febuxostat and Kidney Stones
Febuxostat is particularly appropriate for this patient with kidney stones because:
- Febuxostat reduces 24-hour urinary uric acid excretion by 58.6% compared to 36.4% with allopurinol in stone formers with hyperuricosuria 3
- This greater reduction in urinary uric acid may help prevent future uric acid stone formation
- Both allopurinol and febuxostat reduce serum and urinary uric acid by inhibiting xanthine oxidase, avoiding the increased renal uric acid excretion that occurs with uricosuric agents 4—this is safer for stone formers
Renal Function Considerations
If your patient has any degree of chronic kidney disease (which is common with recurrent stones):
- Febuxostat does not require dose adjustment in mild-to-moderate CKD 5
- The ACR strongly recommends xanthine oxidase inhibitors (allopurinol or febuxostat) over probenecid for patients with CKD stage ≥3 1
- Recent evidence suggests febuxostat may have nephroprotective effects with positive long-term eGFR slopes 6, 7
- Patients with CKD stages 4-5 actually require lower febuxostat doses to achieve target uric acid 8
Practical Management Algorithm
- Check current febuxostat dose: If ≤40 mg daily, increase to 80 mg daily
- Initiate flare prophylaxis: Start colchicine 0.6 mg daily (or NSAIDs/prednisone if colchicine contraindicated) and continue for 3-6 months 1
- Recheck uric acid in 2-4 weeks: Target is <6.0 mg/dL
- Continue titrating: If still above target at 80 mg, consider further dose adjustment or adding a second agent
- Monitor for stones: Encourage hydration; consider 24-hour urine collection to assess urinary uric acid excretion
Common Pitfalls to Avoid
- Don't switch medications unnecessarily: Switching from febuxostat to allopurinol when the issue is simply inadequate dosing adds no benefit and risks confusing the patient
- Don't forget flare prophylaxis: Dose escalation of any urate-lowering therapy increases gout flare risk; prophylaxis is strongly recommended 1
- Don't use uricosuric agents in stone formers: Probenecid increases urinary uric acid excretion and would worsen stone risk 1
The evidence is clear: continue febuxostat, increase the dose to achieve target uric acid <6.0 mg/dL, and add flare prophylaxis during titration.